Dana Farber Cancer Institute

Site:	Dana Farber Cancer Institute	Go to their website
Address:	450 Brookline Ave
City:	Boston
State:	MA
Zip:	02215-5450
Country:	USA

70 trials at this site

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
1	A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma	Completed	Closed	GDC-0980	NCT00854152
1	Phase 1 Study of OSI-930 in Cancer Patients	Completed	Closed	osi-930	NCT00513851
1	PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors	Completed	Closed	PLX9486 + PLX3397	NCT02401815
1	BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	Infigratinib + Imatinib	NCT02257541.
2	A Study of R1507 in Patients With Recurrent or Refractory Sarcoma	Does not allow GIST	Closed	R1507	NCT00642941
3	Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy	No longer avalable	Closed	Regorafenib (BAY 73-4506)	NCT01646593
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
2	Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01068769
1	Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	STA-9090	NCT00688116
1	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.	Ongoing, but not recruiting	Closed	AUY922	NCT00526045
1	Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors	Ongoing, but not recruiting	Closed	XL147	NCT00486135
1	A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable	Ongoing, but not recruiting	Closed	GDC-0941	NCT00876109
1	RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms	Ongoing, but not recruiting	Closed	CP-751,871 + RAD001	NCT00927966
1	A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma	Ongoing, but not recruiting	Closed	GDC-0980	NCT00854126
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
1	A Non-randomized, Open-label, Single-center Phase Ib Study of Short Cycles of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors: SURE Trial	Ongoing, but not recruiting	Closed	Sunitinib + Regorafenib	NCT02164240
1	A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors	Ongoing, but not recruiting	Closed	Cobimetinib + MPDL3280A	NCT01988896
1	A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	KTN0158	NCT02642016
1/2	Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion	Recruiting	Active	MRTX1719	NCT05245500

Dana Farber Cancer Institute

70 trials at this site

First | Previous | Page 3 of 4 | Next | Last